Elanco stock touches 52-week low at $11.11 amid market challenges
Incorporated (NYSE: ELAN) shares have reached a 52-week low, dipping to $11.11, as the company faces a tumultuous market environment. With a market capitalization of $5.55 billion and a beta of 1.42, ...
BioSpace15h
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
Leerink Partners Remains a Buy on Century Therapeutics (IPSC)
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...
Nkarta (NKTX) Gets a Buy from Leerink Partners
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.
Research Analysts Issue Forecasts for UTHR FY2024 Earnings
Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of United Therapeutics in a research report ...